BioCardia said today it closed its merger with Tiger X Medical (OTC:CDOM), with the combined company retaining the BioCardia name and “BCDA” ticker. San Carlos, Calif.-based BioCardia said it converted all outstanding convertible promissory notes into shares of common stock before the merger, putting approximately $25 million in cash in their packets before the payment of […]
Tiger X Medical Inc.
Opko Health gets in on BioCardia after merger with Tiger X Medical
BioCardia said today that Opko Health (NYSE:OPK) agreed to pick up a “significant” stake in its business after a merger with Tiger X Medical (OTC:CDOM). The new company will keep the BioCardia name and the development program for its CardiAMP cell therapy for heart failure patient’s who’ve had a heart attack. Stem cells derived from the bone marrow of […]
Arthrex ponies up $5m royalty payment to Tiger X Medical
Arthrex this month paid $5.6 million in a royalty settlement and release agreement with Tiger X Medical, previously known as Cardo Medical, according to an SEC filing. The payment relates to a previously inked asset purchase agreement, signed in January 2011, in which Arthrex picked up Cardo Medical’s arthroplasty division, including all hip and knee […]
Endologix appoints a new VP of global marketing | Personnel Moves
Endologix (NASDAQ: ELGX), a developer of medical devices for aortic disorders, brought in a new face for the VP of global marketing position.
Echo Therapeutics posts a tough quarter | Earnings Roundup
Echo Therapeutics Inc.’s (OTC:ECTE) grew more than three fold in Q2 as the company poured money into research & development and administrative expenses.
Losses for the quarter widened 262 percent to $1.9 million, or a loss of 6 cents per diluted share, during the three months ended June 30, compared to losses of $536,000, or 2 cents lost per diluted share, during the same period last year.
